Curcumin-based Neurokinin 3 Receptor Modulation for Animal Health
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of curcumin compositions as neurokinin 3 (NK3) antagonists to develop novel applications in animal health, addressing unmet needs in companion animals, agricultural livestock, aquaculture, and poultry.
Background and Problem Solved
The original patent disclosed curcumin compositions as NK3 antagonists for human therapeutic applications. However, the limitations of this technology were restricted to human use cases, leaving a significant gap in addressing similar health issues in animals. This inventive concept solves this problem by exploring new applications and use cases for curcumin-based NK3 receptor modulation in animal health.
Detailed Description of the Inventive Concept
The inventive concept involves the development of curcumin compositions specifically formulated to cross the blood-brain barrier and inhibit NK3 receptor activity in various animal species. This is achieved through the creation of novel formulations, such as veterinary formulations, feed supplements, and aquaculture compositions, which selectively target NK3 receptors in the central nervous system of animals. The new claims encompass a range of applications, including treating neurodegenerative disorders in companion animals, reducing anxiety in agricultural livestock, and improving growth rates in poultry.
Novelty and Inventive Step
The new claims introduce a novel and non-obvious application of curcumin-based NK3 receptor modulation in animal health, distinct from the original patent's focus on human therapeutic applications. The inventive concept's novelty lies in its tailored formulations and targeted delivery mechanisms, which enable effective modulation of NK3 receptors in various animal species.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the development of transdermal patches, injectable formulations, or oral tablets for animal use. Variations could also involve combining curcumin with other natural compounds or pharmacological agents to enhance its efficacy and bioavailability.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the animal health industry, with potential applications in veterinary medicine, agricultural production, and aquaculture. The target market includes animal health companies, veterinarians, farmers, and aquaculture operators seeking innovative solutions to improve animal welfare and productivity.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/9066 |
| A | A61 | A61K31/26 |
| A | A61 | A61K36/82 |
| A | A61 | A61P15/12 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical and veterinary compositions, with expertise in natural compound formulations, receptor pharmacology, and nutraceutical development for animal health applications
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmacology, veterinary medicine, or biochemistry, possessing knowledge of receptor antagonists, natural compound delivery mechanisms, and cross-species therapeutic adaptations
Obviousness Rationale
A PHOSITA would recognize the natural extension of the source patent's curcumin NK3 receptor antagonist technology into veterinary applications, given the well-established principles of receptor pharmacology and the known translational potential of natural compounds across species. The PTD's variations represent predictable adaptations of the core NK3 receptor modulation technology, utilizing standard formulation techniques to target similar physiological mechanisms in different animal systems. The systematic approach of tailoring curcumin compositions for specific animal health applications would be considered a routine optimization within the skill set of a person trained in pharmaceutical development.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,594 |
|---|---|
| Title | Curcumin compositions and methods of use as an NK3 antagonist |
| Assignee(s) | JDS Therapeutics, LLC |